149 related articles for article (PubMed ID: 19016765)
21. Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients.
Ebaid NF; Abdelkawy KS; Shehata MA; Salem HF; Magdy G; Hussein RRS; Elbarbry F
Xenobiotica; 2024 Mar; 54(3):160-170. PubMed ID: 38491961
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours.
Xu L; Wang W; Sheng YC; Zheng QS
J Clin Pharm Ther; 2010 Oct; 35(5):593-601. PubMed ID: 20831683
[TBL] [Abstract][Full Text] [Related]
23. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).
Lakhman SS; Ghosh D; Blanco JG
Drug Metab Dispos; 2005 Feb; 33(2):254-7. PubMed ID: 15537833
[TBL] [Abstract][Full Text] [Related]
24. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.
Hor SY; Lee SC; Wong CI; Lim YW; Lim RC; Wang LZ; Fan L; Guo JY; Lee HS; Goh BC; Tan T
Pharmacogenomics J; 2008 Apr; 8(2):139-46. PubMed ID: 17876342
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
28. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
29. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of doxorubicin in pregnant women.
Ryu RJ; Eyal S; Kaplan HG; Akbarzadeh A; Hays K; Puhl K; Easterling TR; Berg SL; Scorsone KA; Feldman EM; Umans JG; Miodovnik M; Hebert MF
Cancer Chemother Pharmacol; 2014 Apr; 73(4):789-97. PubMed ID: 24531558
[TBL] [Abstract][Full Text] [Related]
32. Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4'-amino-3,5-dihydroxy-trans-stilbene.
Ito Y; Mitani T; Harada N; Isayama A; Tanimori S; Takenaka S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2013; 59(4):358-64. PubMed ID: 24064738
[TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Blanco JG; Leisenring WM; Gonzalez-Covarrubias VM; Kawashima TI; Davies SM; Relling MV; Robison LL; Sklar CA; Stovall M; Bhatia S
Cancer; 2008 Jun; 112(12):2789-95. PubMed ID: 18457324
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis.
El-Hawari Y; Favia AD; Pilka ES; Kisiela M; Oppermann U; Martin HJ; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):234-41. PubMed ID: 19061875
[TBL] [Abstract][Full Text] [Related]
35. Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.
Cui L; Huang J; Zhan Y; Qiu N; Jin H; Li J; Huang H; Li H
Life Sci; 2021 Jul; 276():119392. PubMed ID: 33774021
[TBL] [Abstract][Full Text] [Related]
36. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry.
Dobbs NA; Twelves CJ; Gillies H; James CA; Harper PG; Rubens RD
Cancer Chemother Pharmacol; 1995; 36(6):473-6. PubMed ID: 7554038
[TBL] [Abstract][Full Text] [Related]
37. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
Robert J; Monnier A; Poutignat N; Hérait P
Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
[TBL] [Abstract][Full Text] [Related]
38. Importance of the substrate-binding loop region of human monomeric carbonyl reductases in catalysis and coenzyme binding.
Miura T; Nishinaka T; Terada T
Life Sci; 2009 Aug; 85(7-8):303-8. PubMed ID: 19555696
[TBL] [Abstract][Full Text] [Related]
39. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; McGeary RP; Charles BG
Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
[TBL] [Abstract][Full Text] [Related]
40. Resveratrol reduces the hypoxia-induced resistance to doxorubicin in breast cancer cells.
Mitani T; Ito Y; Harada N; Nakano Y; Inui H; Ashida H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(2):122-8. PubMed ID: 24975222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
